64
|
Romo N, Fitó M, Gumá M, Sala J, García C, Ramos R, Muntasell A, Masiá R, Bruguera J, Subirana I, Vila J, de Groot E, Elosua R, Marrugat J, López-Botet M. Association of Atherosclerosis With Expression of the LILRB1 Receptor By Human NK and T-Cells Supports the Infectious Burden Hypothesis. Arterioscler Thromb Vasc Biol 2011; 31:2314-21. [DOI: 10.1161/atvbaha.111.233288] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Objective—
The contribution of human cytomegalovirus (HCMV) to vascular disease may depend on features of the immune response not reflected by the detection of specific antibodies. Persistent HCMV infection in healthy blood donors has been associated with changes in the distribution of NK cell receptors (NKR). The putative relationship among HCMV infection, NKR distribution, subclinical atherosclerosis, and coronary heart disease was assessed.
Methods and Results—
NKR expression was compared in acute myocardial infarction (AMI) patients (
n
=70) and a population-based control sample (
n
=209). The relationship between NKR expression and carotid intima-media thickness (CIMT) in controls (
n
=149) was also studied. HCMV infection was associated with higher proportions of NKG2C+ and LILRB1+ NK and T-cells. In contrast, only LILRB1+ NK and CD56+ T-cells were found to be increased in AMI patients, independent of age, sex, conventional vascular risk factors, and HCMV seropositivity. Remarkably, LILRB1 expression in NK and T-cells significantly correlated with CIMT in controls.
Conclusion—
The association of overt and subclinical atherosclerotic disease with LILRB1+ NK and T-cells likely reflects a relationship between the immune challenge by infections and cardiovascular disease risk, without attributing a dominant role for HCMV. Our findings may lead to the identification of novel biomarkers of vascular disease.
Collapse
Affiliation(s)
- Neus Romo
- From the Immunology Unit (N.R., M.G., M.L.-B.), University Pompeu Fabra, Barcelona, Spain; IMIM (Hospital del Mar Research Institute) (M.F., A.M., I.S., J.V., R.E., J.M., M.L.-B.), Barcelona, Spain; Department of Cardiology (J.S., R.M.), Hospital Universitari Josep Trueta, Girona, Spain; Department of Cardiology (C.G., J.B.), Hospital del Mar, Barcelona, Spain; Department of Vascular Medicine (E.G.), Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands; CIBER Epidemiology and
| | - Montserrat Fitó
- From the Immunology Unit (N.R., M.G., M.L.-B.), University Pompeu Fabra, Barcelona, Spain; IMIM (Hospital del Mar Research Institute) (M.F., A.M., I.S., J.V., R.E., J.M., M.L.-B.), Barcelona, Spain; Department of Cardiology (J.S., R.M.), Hospital Universitari Josep Trueta, Girona, Spain; Department of Cardiology (C.G., J.B.), Hospital del Mar, Barcelona, Spain; Department of Vascular Medicine (E.G.), Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands; CIBER Epidemiology and
| | - Mónica Gumá
- From the Immunology Unit (N.R., M.G., M.L.-B.), University Pompeu Fabra, Barcelona, Spain; IMIM (Hospital del Mar Research Institute) (M.F., A.M., I.S., J.V., R.E., J.M., M.L.-B.), Barcelona, Spain; Department of Cardiology (J.S., R.M.), Hospital Universitari Josep Trueta, Girona, Spain; Department of Cardiology (C.G., J.B.), Hospital del Mar, Barcelona, Spain; Department of Vascular Medicine (E.G.), Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands; CIBER Epidemiology and
| | - Joan Sala
- From the Immunology Unit (N.R., M.G., M.L.-B.), University Pompeu Fabra, Barcelona, Spain; IMIM (Hospital del Mar Research Institute) (M.F., A.M., I.S., J.V., R.E., J.M., M.L.-B.), Barcelona, Spain; Department of Cardiology (J.S., R.M.), Hospital Universitari Josep Trueta, Girona, Spain; Department of Cardiology (C.G., J.B.), Hospital del Mar, Barcelona, Spain; Department of Vascular Medicine (E.G.), Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands; CIBER Epidemiology and
| | - Cosme García
- From the Immunology Unit (N.R., M.G., M.L.-B.), University Pompeu Fabra, Barcelona, Spain; IMIM (Hospital del Mar Research Institute) (M.F., A.M., I.S., J.V., R.E., J.M., M.L.-B.), Barcelona, Spain; Department of Cardiology (J.S., R.M.), Hospital Universitari Josep Trueta, Girona, Spain; Department of Cardiology (C.G., J.B.), Hospital del Mar, Barcelona, Spain; Department of Vascular Medicine (E.G.), Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands; CIBER Epidemiology and
| | - Rafel Ramos
- From the Immunology Unit (N.R., M.G., M.L.-B.), University Pompeu Fabra, Barcelona, Spain; IMIM (Hospital del Mar Research Institute) (M.F., A.M., I.S., J.V., R.E., J.M., M.L.-B.), Barcelona, Spain; Department of Cardiology (J.S., R.M.), Hospital Universitari Josep Trueta, Girona, Spain; Department of Cardiology (C.G., J.B.), Hospital del Mar, Barcelona, Spain; Department of Vascular Medicine (E.G.), Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands; CIBER Epidemiology and
| | - Aura Muntasell
- From the Immunology Unit (N.R., M.G., M.L.-B.), University Pompeu Fabra, Barcelona, Spain; IMIM (Hospital del Mar Research Institute) (M.F., A.M., I.S., J.V., R.E., J.M., M.L.-B.), Barcelona, Spain; Department of Cardiology (J.S., R.M.), Hospital Universitari Josep Trueta, Girona, Spain; Department of Cardiology (C.G., J.B.), Hospital del Mar, Barcelona, Spain; Department of Vascular Medicine (E.G.), Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands; CIBER Epidemiology and
| | - Rafel Masiá
- From the Immunology Unit (N.R., M.G., M.L.-B.), University Pompeu Fabra, Barcelona, Spain; IMIM (Hospital del Mar Research Institute) (M.F., A.M., I.S., J.V., R.E., J.M., M.L.-B.), Barcelona, Spain; Department of Cardiology (J.S., R.M.), Hospital Universitari Josep Trueta, Girona, Spain; Department of Cardiology (C.G., J.B.), Hospital del Mar, Barcelona, Spain; Department of Vascular Medicine (E.G.), Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands; CIBER Epidemiology and
| | - Jordi Bruguera
- From the Immunology Unit (N.R., M.G., M.L.-B.), University Pompeu Fabra, Barcelona, Spain; IMIM (Hospital del Mar Research Institute) (M.F., A.M., I.S., J.V., R.E., J.M., M.L.-B.), Barcelona, Spain; Department of Cardiology (J.S., R.M.), Hospital Universitari Josep Trueta, Girona, Spain; Department of Cardiology (C.G., J.B.), Hospital del Mar, Barcelona, Spain; Department of Vascular Medicine (E.G.), Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands; CIBER Epidemiology and
| | - Isaac Subirana
- From the Immunology Unit (N.R., M.G., M.L.-B.), University Pompeu Fabra, Barcelona, Spain; IMIM (Hospital del Mar Research Institute) (M.F., A.M., I.S., J.V., R.E., J.M., M.L.-B.), Barcelona, Spain; Department of Cardiology (J.S., R.M.), Hospital Universitari Josep Trueta, Girona, Spain; Department of Cardiology (C.G., J.B.), Hospital del Mar, Barcelona, Spain; Department of Vascular Medicine (E.G.), Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands; CIBER Epidemiology and
| | - Joan Vila
- From the Immunology Unit (N.R., M.G., M.L.-B.), University Pompeu Fabra, Barcelona, Spain; IMIM (Hospital del Mar Research Institute) (M.F., A.M., I.S., J.V., R.E., J.M., M.L.-B.), Barcelona, Spain; Department of Cardiology (J.S., R.M.), Hospital Universitari Josep Trueta, Girona, Spain; Department of Cardiology (C.G., J.B.), Hospital del Mar, Barcelona, Spain; Department of Vascular Medicine (E.G.), Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands; CIBER Epidemiology and
| | - Eric de Groot
- From the Immunology Unit (N.R., M.G., M.L.-B.), University Pompeu Fabra, Barcelona, Spain; IMIM (Hospital del Mar Research Institute) (M.F., A.M., I.S., J.V., R.E., J.M., M.L.-B.), Barcelona, Spain; Department of Cardiology (J.S., R.M.), Hospital Universitari Josep Trueta, Girona, Spain; Department of Cardiology (C.G., J.B.), Hospital del Mar, Barcelona, Spain; Department of Vascular Medicine (E.G.), Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands; CIBER Epidemiology and
| | - Roberto Elosua
- From the Immunology Unit (N.R., M.G., M.L.-B.), University Pompeu Fabra, Barcelona, Spain; IMIM (Hospital del Mar Research Institute) (M.F., A.M., I.S., J.V., R.E., J.M., M.L.-B.), Barcelona, Spain; Department of Cardiology (J.S., R.M.), Hospital Universitari Josep Trueta, Girona, Spain; Department of Cardiology (C.G., J.B.), Hospital del Mar, Barcelona, Spain; Department of Vascular Medicine (E.G.), Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands; CIBER Epidemiology and
| | - Jaume Marrugat
- From the Immunology Unit (N.R., M.G., M.L.-B.), University Pompeu Fabra, Barcelona, Spain; IMIM (Hospital del Mar Research Institute) (M.F., A.M., I.S., J.V., R.E., J.M., M.L.-B.), Barcelona, Spain; Department of Cardiology (J.S., R.M.), Hospital Universitari Josep Trueta, Girona, Spain; Department of Cardiology (C.G., J.B.), Hospital del Mar, Barcelona, Spain; Department of Vascular Medicine (E.G.), Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands; CIBER Epidemiology and
| | - Miguel López-Botet
- From the Immunology Unit (N.R., M.G., M.L.-B.), University Pompeu Fabra, Barcelona, Spain; IMIM (Hospital del Mar Research Institute) (M.F., A.M., I.S., J.V., R.E., J.M., M.L.-B.), Barcelona, Spain; Department of Cardiology (J.S., R.M.), Hospital Universitari Josep Trueta, Girona, Spain; Department of Cardiology (C.G., J.B.), Hospital del Mar, Barcelona, Spain; Department of Vascular Medicine (E.G.), Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands; CIBER Epidemiology and
| |
Collapse
|